906 related articles for article (PubMed ID: 25708216)
1. Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease.
Wang B; Hu Y; Liu L; Hu K; Tie R; He Y; Fu S; Zhu N; Luo Y; Yu X; Huang H
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1020-8. PubMed ID: 25708216
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
3. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience.
Delia M; Pastore D; Mestice A; Carluccio P; Perrone T; Gaudio F; Ricco A; Sgherza N; Albano F; Specchia G
Biol Blood Marrow Transplant; 2013 Mar; 19(3):495-9. PubMed ID: 23200706
[TBL] [Abstract][Full Text] [Related]
4. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
[TBL] [Abstract][Full Text] [Related]
5. Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis.
Kuzmina LA; Petinati NA; Shipounova IN; Sats NV; Bigildeev AE; Zezina EA; Popova MD; Drize NJ; Parovichnikova EN; Savchenko VG
Eur J Haematol; 2016 Apr; 96(4):425-34. PubMed ID: 26115424
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effect of bone marrow mesenchymal stem cells on T lymphocytes in patients with decompensated liver cirrhosis.
Guo CH; Han LX; Wan MR; Deng GJ; Gan JH
Genet Mol Res; 2015 Jun; 14(2):7039-46. PubMed ID: 26125913
[TBL] [Abstract][Full Text] [Related]
7. Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity.
Copland IB; Qayed M; Garcia MA; Galipeau J; Waller EK
Biol Blood Marrow Transplant; 2015 May; 21(5):934-40. PubMed ID: 25659882
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats.
Kitazawa Y; Li XK; Xie L; Zhu P; Kimura H; Takahara S
Cell Transplant; 2012; 21(2-3):581-90. PubMed ID: 22793067
[TBL] [Abstract][Full Text] [Related]
9. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease.
Yañez R; Lamana ML; García-Castro J; Colmenero I; Ramírez M; Bueren JA
Stem Cells; 2006 Nov; 24(11):2582-91. PubMed ID: 16873762
[TBL] [Abstract][Full Text] [Related]
10. Phase II Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease After HLA-Haploidentical Stem-Cell Transplantation.
Gao L; Zhang Y; Hu B; Liu J; Kong P; Lou S; Su Y; Yang T; Li H; Liu Y; Zhang C; Gao L; Zhu L; Wen Q; Wang P; Chen X; Zhong J; Zhang X
J Clin Oncol; 2016 Aug; 34(24):2843-50. PubMed ID: 27400949
[TBL] [Abstract][Full Text] [Related]
11. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.
Zhang D; Li H; Ma L; Zhang X; Xue F; Zhou Z; Chi Y; Liu X; Huang Y; Yang Y; Yang R
Autoimmunity; 2014 Dec; 47(8):519-29. PubMed ID: 25019270
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
13. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
14. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
15. [Association of the ratio of regulatory and effector T cells with recurrence and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
Wang HT; Zhao XY; Zhao XS; Han TT; Lv M; Chang YJ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):679-84. PubMed ID: 23978019
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.
Rettinger E; Huenecke S; Bonig H; Merker M; Jarisch A; Soerensen J; Willasch A; Bug G; Schulz A; Klingebiel T; Bader P
Haematologica; 2016 Apr; 101(4):e153-6. PubMed ID: 26768688
[No Abstract] [Full Text] [Related]
18. The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease.
Gao L; Liu F; Tan L; Liu T; Chen Z; Shi C
Biomaterials; 2014 Apr; 35(11):3582-8. PubMed ID: 24468404
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation.
Mensen A; Oh Y; Becker SC; Hemmati PG; Jehn C; Westermann J; Szyska M; Göldner H; Dörken B; Scheibenbogen C; Arnold R; Na IK
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1895-906. PubMed ID: 26271190
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
